Biodistribution of amphotericin B when delivered through cholesterol hemisuccinate vesicles in normal and A. Fumigatus infected mice

Pharmaceutical Research

Volumn 17, Issue 10, 2000, Pages 1236-1242

  Saxena, Sandeep ^a   Ghosh, Prahlad C ^a  

^a UNIVERSITY OF DELHI   (India)

Author keywords

Amphotericin B; Aspergillosis; Biodistribution; Cholesterol hemisuccinate; Liposomes; Pharmacokinetics

Indexed keywords

AMPHOTERICIN B CHOLESTEROL HEMISUCCINATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPERGILLOSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BUFFERS; CHOLESTEROL ESTERS; DEOXYCHOLIC ACID; DETERGENTS; DRUG CARRIERS; DRUG STABILITY; MALE; MICE; MICE, INBRED BALB C; SUSPENSIONS; TISSUE DISTRIBUTION;

EID: 0033636762     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026418814417     Document Type: Article

References (26)

1. Anti-fungal agents useful in therapy of systemic fungal infections
2. Polyene antibiotic-sterol interactions in membrane of Acholeplasma ladlawii cells and lecithin liposomes. I. Specificity of the membrane permeability changes induced by polyene antibiotics
3. Antifungal and surgical treatment of invasive aspergillosis: Review of 2,121 published cases
4. A review of complications of amphotericin B therapy: Recommendations for prevention and management
5. Lipid formulations of amphotericin B: Recent progress and future directions
6. Liposomal and lipid formulations of amphotericin B: Clinical pharmacokinetics
7. Clinical use of liposomal and lipid-complexed amphotericin B
8. Lipid-based amphotericin B formulations: From animals to man
9. Amphotericin B lipid complex therapy of experimental fungal infections in mice
10. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats
11. Novel antifungal drug delivery: Stable amphotericin B - Cholesteryl sulfate discs
12. Therapeutic evaluation of free and liposomal encapsulated amphotericin B in the treatment of systemic candidiasis in mice
13. Tissue distribution of amphotericin B lipid complex in laboratory animals
14. Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs
15. Toxicity and therapeutic efficacy of amphotericin B delivered through cholesterol hemisuccinate vesicles in the treatment of experimental murine aspergillosis
16. Activity and stability studies of ultrafine nonoencapsulated catalase and penicillinase
17. Quantitation of amphotericin B with use of high-pressure liquid chromatography
18. In vivo potentiation of ricin toxicity by monensin delivered through liposomes
19. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro
20. Mannosylated liposome-mediated delivery of amphotericin-B in the control of experimental aspergillosis in balb/c mice
21. Comparative tissue distribution and elimination of amphotericin B colloidal dispersion (amphocil) and fungizone after repeated dosing in rats
22. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (am-Bisome) in rabbits
23. Altered tissue distribution and elimination of amaikacin encapsulated in unilamellar, low-clearance liposomes (mikasome)
24. Technetium-labeled liposome imaging for deep-seated infection